Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol acetate for weight loss in patients with primary and mixed dementia
2006-005759-13Phase 3Completed
- Sponsor
- Madaus GmbH
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Dementia comparing Megestrol acetate 320 mg/day with Placebo (2 arms). Primary endpoint: Change in body weight at 24 weeks. Started Mar 2010; status: completed.
02
Drugs
megestrol
03
Conditions
Dementia
Beyond the preview
Go deeper on 2006-005759-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005759-13.